


Claims:

1. A compound having the general structure:



10 wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;


R_3 is hydroxy or $-OCONH_2$; and

R_4 is hydroxy or carbonyl.

- 15 2. The compound of claim 1 wherein R_1 is H or halo; and R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy.

- 20 3. The compound of claim 2 wherein R_4 , R_7 and R_8 are H; and R_1 is H or F.

4. A compound having the general structure:



wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and



R_3 is hydroxy or $-OCONH_2$, with the proviso that at least one of R_1 , R_7 and R_8 is other than H.

- 30 5. The compound of claim 4 wherein R_7 and R_8 are H; R_1 is F; and

-36-

R_3 is hydroxy or $-OCONH_2$.

6. A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein R_1 , R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-OCONH_2$; and

R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H.

7. The method of claim 6 wherein said compound has the general structure




wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

- 5 8. The method of claim 7 wherein R_1 is H; and
 R_3 is $-OCONH_2$.

9. A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein R_1 , R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-OCONH_2$; and


- 25 R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H..

10. The method of claim 9 wherein said compound has the general structure

-38-



or



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.



11. The method of claim 10 wherein R_1 is H; and R_3 is $-OCONH_2$.

12. The method of claim 9 wherein the localized hypoxic condition is caused by cerebral ischemia.

13. The method of claim 9 wherein the localized hypoxic condition is caused by myocardial ischemia.

14. A pharmaceutical composition comprising a compound selected from the group consisting of

-39-





wherein R_1 , R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-CONH_2$; and

R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H; and

a pharmaceutically acceptable carrier,.

15. The composition of claim 14 wherein said compound has the general structure



-40-

wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

5 16. The composition of claim 15 wherein R_1 is selected from the group consisting of halo, haloalkyl and hydroxy.

17. The composition of claim 15 wherein R_1 is H; and
 R_3 is $-OCONH_2$.

10

T06000-12252660